Results 1 to 10 of about 14,897 (305)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells

open access: yesFrontiers in Endocrinology, 2022
The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors. In vitro studies demonstrated that everolimus inhibited pituitary neuroendocrine tumor (PitNET) cell growth in
Federica Mangili   +18 more
doaj   +2 more sources

Hypersomatotropism and Hypercortisolism Caused by a Plurihormonal Pituitary Adenoma in a Dog. [PDF]

open access: yesJ Vet Intern Med
ABSTRACT A 12‐year‐old, male Labrador Retriever was presented because of polyuria, polydipsia, polyphagia, joint pain, and physical features consistent with acromegaly. Circulating insulin‐like growth factor‐1 (IGF‐1) concentration was increased (> 1000 ng/mL; reference interval [RI], 42–449), suggestive of hypersomatotropism.
Soler Arias EA   +3 more
europepmc   +2 more sources

Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial. [PDF]

open access: yesPLoS ONE
BackgroundBeneficial effects of dopamine agonist treatment on migraine have been reported but remain to be properly tested. The aim of this study was to examine the effect of cabergoline as preventive treatment for migraine.MethodsIn a double-blind ...
Astrid Johannesson Hjelholt   +5 more
doaj   +2 more sources

Cabergoline Use and Pregnancy Outcomes: A Systematic Review. [PDF]

open access: yesBirth Defects Res
ABSTRACT Introduction Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated.
Otis AS   +4 more
europepmc   +2 more sources

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

open access: yesBMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr   +6 more
doaj   +2 more sources

Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial [PDF]

open access: yesJournal of Ovarian Research
Background This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.
Elnaz Salari   +4 more
doaj   +2 more sources

The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma

open access: yesFertility & Reproduction, 2021
Background: New vessel formation or neovascularization has been recognized as a feature of endometriosis. Treatment with cabergoline suppresses cell proliferation and vascular-endothelial-growth-factor-mediated angiogenesis, thereby promoting regression ...
Mehnaz Mustary Shume   +5 more
doaj   +1 more source

Electrocatalytic determination of levodopa in presence of cabergoline using carbon paste electrode modified with graphene quantum dots/2-chlorobenzoyl ferrocene/ionic liquid

open access: yesJournal of Electrochemical Science and Engineering, 2021
The electrochemical sensor was fabricated for the simultaneous determination of levodopa and cabergoline using carbon paste electrode (CPE) modified with graphene quantum dots (GQD), 2-chlorobenzoyl ferrocene (2CBF) and ionic liquid (IL).
Peyman Mohammadzadeh Jahani
doaj   +1 more source

Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. [PDF]

open access: yesPLoS ONE, 2014
Several lines of evidence demonstrate that oxidative stress is involved in the pathogenesis of neurodegenerative diseases, including Parkinson's disease. Potent antioxidants may therefore be effective in the treatment of such diseases.
Haruki Odaka   +7 more
doaj   +1 more source

A Combination of Exercise and Therapy with Cabergoline Attenuate Disturbances of Pituitary-Gonadal Hormones in Hyperprolactinemic Male Patients [PDF]

open access: yesMontenegrin Journal of Sports Science and Medicine, 2020
This study aimed to investigate whether cabergoline therapy alone for six months or in combination with a light exercise programme for an additional three months can attenuate hyperprolactinemia in 13 male patients (range: 22 to 45 yrs.) through ...
Mohammad Fayiz AbuMoh'd   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy